BRPI0400192A - Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina - Google Patents

Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina

Info

Publication number
BRPI0400192A
BRPI0400192A BR0400192-3A BRPI0400192A BRPI0400192A BR PI0400192 A BRPI0400192 A BR PI0400192A BR PI0400192 A BRPI0400192 A BR PI0400192A BR PI0400192 A BRPI0400192 A BR PI0400192A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
evasins
derivatives
acetylcholine receptor
analogs
Prior art date
Application number
BR0400192-3A
Other languages
English (en)
Inventor
Mirian Akemi Furuie Hayashi
Antonio Carlos Martins Camargo
Alexander Henning Ulrich
Ruben Dario Sinisterra Millan
Robson Augusto Souza Do Santos
Danielle Alves Ianzer
Raphael Dos Reis Marioni
Original Assignee
Biolab Sanus Farmaceutica Ltda
Mirian Akemi Furuie Hayashi
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda, Mirian Akemi Furuie Hayashi, Fundacao De Amparo A Pesquisa filed Critical Biolab Sanus Farmaceutica Ltda
Priority to BR0400192-3A priority Critical patent/BRPI0400192A/pt
Priority to PCT/BR2005/000015 priority patent/WO2005081613A2/en
Publication of BRPI0400192A publication Critical patent/BRPI0400192A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS DE PEPTìDEOS, SECRETADOS PELAS GLâNDULAS DO VENENO DE SERPENTES, PARTICULARMENTE DA BOTHROPS JARARACA, EVASINS, SEUS ANáLOGOS, DERIVADOS E PRODUTOS ASSOCIADOS PARA USO COMO AGENTES MODULADORES DOS RECEPTORES DE ACETILCOLINA". A presente invenção caracteriza-se pelo uso das composições farmacêuticas dos peptídeos secretados pelo veneno da cobra, particularmente da Bothrops Jararaca, EVASINS, seus análogos e derivados e produtos associados como agentes moduladores dos receptores de acetilcolina. As composições farmacêuticas da presente invenção caracterizam-se por poderem atuar como agonistas, agonistas parciais, antagonistas ou moduladores alostéricos do receptor de acetilcolina. As composições farmacêuticas dos EVASINS compreendem ainda o seu uso como protetores dos receptores de acetilcolina da ação de drogas de abuso como cocaína ou fenciclicina, de toxinas como filantoxinas ou cembranóides isolados de corais ou tabaco, ou ainda de toxinas de aranhas. As composições farmacêuticas dos EVASINS caracterizam-se por poder prevenir a cocaína de se ligar ao AchR. As composições farmacêuticas dos EVASINS e seus análogos estruturais e/ou conformacionais caracterizado pela utilização dos EVASINS e seus respectivos análogos e derivados compreendem o seu uso como modelos moleculares para o desenvolvimento de fármacos e/ou composições farmacêuticas com base em compostos peptídicos e/ou não-peptídicos para uso no diagnóstico, prevenção, estudo e tratamento de doenças associadas com a disfunção dos receptores colinérgicos. As composições farmacêuticas dos referidos EVASINS, seus análogos e derivados incluídos em ciclodextrinas ou seus derivados, desta patente apresentam um aumento da biodisponibilidade, duração e/ou eficácia dos efeitos moduladores dos receptores de acetilcolina quando administrados por diferentes vias de aplicação como oral, intravenosa, intramuscular, nasal, subcutânea, transdêrmica, como exemplos não limitantes.
BR0400192-3A 2004-02-11 2004-02-11 Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina BRPI0400192A (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR0400192-3A BRPI0400192A (pt) 2004-02-11 2004-02-11 Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina
PCT/BR2005/000015 WO2005081613A2 (en) 2004-02-11 2005-02-04 Pharmaceutical compositions of peptides secreted by the venom glands of snakes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0400192-3A BRPI0400192A (pt) 2004-02-11 2004-02-11 Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina

Publications (1)

Publication Number Publication Date
BRPI0400192A true BRPI0400192A (pt) 2005-10-04

Family

ID=34891708

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0400192-3A BRPI0400192A (pt) 2004-02-11 2004-02-11 Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina

Country Status (2)

Country Link
BR (1) BRPI0400192A (pt)
WO (1) WO2005081613A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539018A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
CN108830883B (zh) * 2018-06-05 2022-04-01 成都信息工程大学 基于超像素结构的视觉注意sar图像目标检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819831A (en) * 1969-06-30 1974-06-25 Squibb & Sons Inc Angiotensin converting enzyme inhibitor-fractionated snake venom
BR0101088A (pt) * 2001-03-19 2003-03-18 Biolab Sanus Farmaceutica Ltda Processo de isolamento e purificação de peptìdeos inibidores das vasopeptidases, com especificidade para o sìtio carboxìlico da enzima conversora da angiotensina, secretados pelas glândulas do veneno de serpentes (bpps), particularmente bothrops jararaca, ou produzidos endogenamente (evasins) possuindo ação vasodilatadora e anti-hipertensiva; processo de determinação da sequência de amido-ácidos dos peptìdios inibidores secretados pela glândula de veneno de serpentes (bpps) ou endógenos (evasins); processo de determinação da sequência de aminoácidos dos bpps por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca. processo de determinação da sequência de aminoácidos dos evasins por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca, processo de amplificação do cdna a partir das bibliotecas de cdna de pâncreas e/ou cérebro de serpentes, especificamente bothrops jararaca; processo de sìntese em fase sólida de peptìdeos inibidores das vasopeptidases com ação vasodilatadora e anti-hipertensiva, peptìdeos inibidores das vasopeptidases com ação anti-hipertensiva; utilização dos peptìdeos inibidores das vaso peptidases com ação vasodilatadora e anti-hipertensiva na obtenção de composições farmacêuticas; processo de determinação da atividade inibitória sobre as vasopeptidases e de atividade biológica sobre músculo liso, sistema cardiovascular e microcirculatório.

Also Published As

Publication number Publication date
WO2005081613A2 (en) 2005-09-09
WO2005081613A3 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
D Levin α7-Nicotinic receptors and cognition
JP7220259B2 (ja) 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールｔｒｐｖ１アゴニストのプロドラッグ
Nichols et al. Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1–13) or MK-801 in a nerve-ligation model of peripheral neuropathy
ES2322725T3 (es) Composiciones farmaceuticas que contienen un analogo de la nicotina y un inhibidor de la acetilcolinesterasa para la prevencion y el tratamiento de trastornos en el sistema nervioso central.
Kim et al. Relieving effects of electroacupuncture on mechanical allodynia in neuropathic pain model of inferior caudal trunk injury in rat: mediation by spinal opioid receptors
Avenet et al. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes
Boettger et al. Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis
Kim et al. Antinociceptive mechanisms associated with diluted bee venom acupuncture (apipuncture) in the rat formalin test: involvement of descending adrenergic and serotonergic pathways
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
Fiorino et al. Muscarinic pain pharmacology: realizing the promise of novel analgesics by overcoming old challenges
BRPI0807232A2 (pt) Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
Altier et al. Intra-VTA infusions of the substance P analogue, DiMe-C7, and intra-accumbens infusions of amphetamine induce analgesia in the formalin test for tonic pain
Kishi et al. Spermidine, a polyamine site agonist, attenuates working memory deficits caused by blockade of hippocampal muscarinic receptors and mGluRs in rats
AR048573A1 (es) Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
Shueb et al. Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5
US20140094413A1 (en) Hepatocyte growth factor (hgf) mimics as therapeutic agents
PT2212349E (pt) Análogos sintéticos de péptidos de regeneração neural
US9725484B2 (en) Methods and compositions for the treatment of bone remodeling disorders
Leone et al. The analgesic activity of biphalin and its analog AM 94 in rats
Trailovic et al. Ivermectin effects on motor coordination and contractions of isolated rat diaphragm
BRPI0400192A (pt) Composições farmacêuticas de peptìdeos, secretados pelas glândulas do veneno de serpentes, particularmente da bothrops jararaca, evasins, seus análogos, derivados e produtos associados para uso como agentes moduladores dos receptores de acetilcolina
Uslu et al. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism
US6670356B2 (en) Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
Li et al. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]